Li Kang Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	589.21	565.52	629.38	684.25	386.97
Revenue Growth (YoY)	4.19%	-10.15%	-8.02%	76.82%	-15.27%
Cost of Revenue	190.96	179.42	203.23	295.68	122.29
Gross Profit	398.25	386.1	426.15	388.58	264.68
Selling, General & Admin	299.97	296.08	292.77	251.22	207.44
Operating Expenses	299.97	296.08	292.77	251.22	207.44
Operating Income	98.28	90.02	133.37	137.36	57.25
Interest Expense	-0.37	-0.69	-0.62	-0.29	-0.46
Interest & Investment Income	4.67	6.37	3.29	1.6	2.21
Currency Exchange Gain (Loss)	-0.46	0.64	0.02	0.96	-0.22
Other Non Operating Income (Expenses)	2.39	2.58	2.19	3.35	1.69
EBT Excluding Unusual Items	104.51	98.91	138.25	142.98	60.48
Gain (Loss) on Sale of Investments	-0.46	0.28	0.9	-2.2	-1.75
Other Unusual Items	-	-	-	0.02	4.76
Pretax Income	104.05	99.19	139.14	140.8	63.48
Income Tax Expense	20.23	22.16	28.15	28.7	12.05
Net Income	83.82	77.02	110.99	112.09	51.44
Net Income to Common	83.82	77.02	110.99	112.09	51.44
Net Income Growth	8.83%	-30.61%	-0.98%	117.92%	-25.74%
Shares Outstanding (Basic)	32	31	27	27	27
Shares Outstanding (Diluted)	32	31	27	27	27
Shares Change (YoY)	2.50%	15.70%	-	0.10%	-0.23%
EPS (Basic)	2.64	2.48	4.14	4.18	1.92
EPS (Diluted)	2.62	2.47	4.12	4.16	1.91
EPS Growth	6.07%	-40.05%	-0.96%	117.46%	-25.49%
Free Cash Flow	-237.23	2.63	93.48	156.08	56.19
Free Cash Flow Per Share	-7.42	0.08	3.47	5.79	2.09
Dividend Per Share	2.000	2.000	2.500	1.739	1.242
Dividend Growth	-	-20.00%	43.75%	40.00%	-46.43%
Gross Margin	67.59%	68.27%	67.71%	56.79%	68.40%
Operating Margin	16.68%	15.92%	21.19%	20.07%	14.79%
Profit Margin	14.23%	13.62%	17.64%	16.38%	13.29%
Free Cash Flow Margin	-40.26%	0.46%	14.85%	22.81%	14.52%
EBITDA	107.08	100.38	143.05	148.35	70.14
EBITDA Margin	18.17%	17.75%	22.73%	21.68%	18.12%
D&A For EBITDA	8.79	10.36	9.68	10.99	12.89
EBIT	98.28	90.02	133.37	137.36	57.25
EBIT Margin	16.68%	15.92%	21.19%	20.07%	14.79%
Effective Tax Rate	19.44%	22.35%	20.23%	20.39%	18.97%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.